Jiang Dan, Tang Guo-Du, Lai Ming-Yu, Huang Zhen-Ning, Liang Zhi-Hai
Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
World J Clin Cases. 2021 May 16;9(14):3466-3471. doi: 10.12998/wjcc.v9.i14.3466.
Cronkhite-Canada syndrome (CCS) is a rare nonhereditary disease characterized by chronic diarrhoea, diffuse gastrointestinal polyposis and ectodermal manifestations. The lethality of CCS can be up to 50% if it is untreated or if treatment is delayed or inadequate. More than 35% of the patients do not achieve long-term clinical remission after corticosteroid administration, with relapse occurring during or after the cessation of glucocorticoid use. The optimal strategy of maintenance therapy of this disease is controversial.
A 47-year-old man presented to the hospital with a 3-mo history of frequent watery diarrhoea, accompanied by macular skin pigmentation that included the palms and soles, and onychodystrophy of the fingernails and toenails. Gastroscopy and colonoscopy revealed numerous polyps in the stomach and colon. After other possibilities were ruled out by a series of examinations, CCS was diagnosed and treated with prednisone. The patient took prednisone for more than 1 year before achieving complete resolution of his symptoms and endoscopic findings. The patient was then given prednisone 5 mg/d for 6 mo of maintenance therapy. With clinical improvement and polyp regression, prednisone was discontinued. Eight mo after the discontinuation of prednisone, the diarrhoea and gastrointestinal polyps relapsed. Therefore, the patient was given the same dose of prednisone, and complete remission was achieved again.
It is necessary to extend the duration of prednisone maintenance therapy for CCS. Prednisone is still effective when readministered after relapse. Surveillance endoscopy at intervals of 1 year or less is recommended to assess mucosal disease activity.
克朗凯特-加拿大综合征(CCS)是一种罕见的非遗传性疾病,其特征为慢性腹泻、弥漫性胃肠道息肉病和外胚层表现。如果不治疗或治疗延迟或不充分,CCS的致死率可达50%。超过35%的患者在使用糖皮质激素后未实现长期临床缓解,在糖皮质激素使用期间或停用后会复发。这种疾病维持治疗的最佳策略存在争议。
一名47岁男性因3个月频繁水样腹泻病史入院,伴有手掌和足底的斑片状皮肤色素沉着以及指甲和趾甲的甲营养不良。胃镜和结肠镜检查显示胃和结肠有大量息肉。经过一系列检查排除其他可能性后,诊断为CCS并给予泼尼松治疗。患者服用泼尼松1年多后症状和内镜检查结果完全缓解。然后给予患者泼尼松5mg/d进行6个月的维持治疗。随着临床症状改善和息肉消退,停用泼尼松。停用泼尼松8个月后,腹泻和胃肠道息肉复发。因此,再次给予患者相同剂量的泼尼松,再次实现完全缓解。
有必要延长CCS患者泼尼松维持治疗的时间。复发后再次使用泼尼松仍然有效。建议每隔1年或更短时间进行监测性内镜检查以评估黏膜疾病活动度。